LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the first patients have been treated in the SYMMETRYSM trial – Synta Metastatic Melanoma Elesclomol Trial – a global, pivotal Phase 3 clinical trial to evaluate the safety and efficacy of elesclomol (formerly STA-4783) in patients with stage IV metastatic melanoma. Synta also reported that it has successfully completed the Special Protocol Assessment (SPA) process, reaching agreement with the FDA on the design, conduct, and planned analyses of the trial.
